Pfizer to close UK R&D site in surprise move
December 4, 2015Research and Development, Sales and Marketing Pfizer
Two weeks after its $160 billion buyout of botox-maker Allergan, Pfizer has announced that it is to close a UK …
New regulatory submissions for AbbVie and Novo Nordisk
December 4, 2015Medical Communications AbbVie, EMA, FDA, Novo Nordisk, Viekira Pak, insulin aspart
AbbVie and Novo Nordisk have submitted new drug applications to the US FDA and European Medicines Agency (EMA) respectively. The …
OBN appoints Dr John Harris as chief executive
December 4, 2015Medical Communications, Sales and Marketing OBN
OBN, the membership organisation supporting the UK’s emerging life sciences companies, has appointed Dr John Harris as its new chief executive, replacing …
Teva strips $1 billion worth of assets to clear Allergan deal
December 4, 2015Medical Communications, Sales and Marketing Allergan, Teva, acquisitions, divestments, mergers
Teva Pharmaceuticals is thought to be in the process of stripping nearly $1 billion worth of assets to address antitrust …
NICE backtracks on Novartis Farydak decision
December 4, 2015Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat
NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …
Cancer drugs prices vary up to 388% between high-income countries
December 4, 2015Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
Big Pharma taking steps towards fully digital businesses
December 3, 2015Medical Communications Accenture, digital pharma, innovation
Pharma companies can tap into $100 billion of revenue from being ‘digital transformers’, and not just ‘digital followers’, a leading …
Chief scientific officers appointed at dementia Drug Discovery Alliance
December 3, 2015Medical Communications, Research and Development Alzheimer's Research, dementia, dementia drug discovery alliance
Alzheimer’s Research UK has appointed three chief scientific officers to drive its £30million Drug Discovery Alliance. The Alliance, which unites …
Katja Stout joins Citigate Dewe Rogerson as director
December 3, 2015Medical Communications Citigate Dewe Rogerson
Citigate Dewe Rogerson has appointed of Katja Stout (previously Toon) as a director in its life sciences team. Katja is …
Alkermes aims to take the next biotech step
December 3, 2015Medical Communications, Research and Development Alkermes
“We think we can be the next Biogen, or a Celgene or a Vertex – we have that much firepower …
NICE turns down bone disorder drug for NHS
December 3, 2015Research and Development Alexion, NICE, Strensiq
NICE has published draft guidance as part of its highly specialised technologies programme, not recommending Alexion Pharma’s Strensiq (asfotase alfa) …
GSK collaborates on ‘smart inhaler’ technology for respiratory trials
December 3, 2015Research and Development COPD, GSK, Propeller, Propeller Health, asthma, clinical trials, ellipta, inhalers, smart drugs, smart inhalers
GSK has entered the ‘smart drug’ industry by partnering with a health technology company to develop a sensor for use …
GSK gets European approval for asthma treatment Nucala
December 3, 2015Research and Development GSK, Nucala, asthma
GlaxoSmithKline has received marketing authorisation from the European Commission for Nucala as an add-on treatment for severe refractory eosinophilic asthma …
Janssen in new collaboration to take on TB
December 3, 2015Research and Development FIND, Janssen, antibiotic resistance, tuberculosis
Janssen has announced a new collaboration with the non-profit organisation FIND to step-up the fight against the public health threat …
Second patient dies in Zafgen obesity trial
December 3, 2015Research and Development
Zafgen has announced the death of a second participant in a Phase III clinical trial of its obesity drug beloranib …
Novo Nordisk buys Xoma diabetes program and scores trial successes
December 2, 2015Research and Development, Sales and Marketing Novo Nordisk, Ryzodeg, SGLT2 inhibitors, Victoza, Xoma, diabetes
Novo Nordisk has announced its purchase of a type 2 diabetes diabetes program in a deal with biotech firm Xoma …
Horizon receives European go-ahead for Ravicti
December 2, 2015Research and Development, Sales and Marketing Horizon Pharma, Ravicti, horizon, orphan drug, rare disease, urea cycle disorders
The European Commission has approved Ravicti for rare urea cycle disorders. Ravicti, (glycerol phenylbutyrate), is an oral liquid developed by Horizon …
Personalised care key to diabetes management, says NICE
December 2, 2015Research and Development NICE, NICE guidelines, diabetes, type 2 diabetes
UK drugs regulator NICE has published updated guidelines on type 2 diabetes, saying that taking an individualised approach to care …
Pfizer lung cancer treatment gets expanded EU approval
December 1, 2015Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer
Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …
J&J announces new partnerships in fight against HIV/AIDS
December 1, 2015Research and Development AIDS, HIV, Janssen
Johnson &Johnson is entering four new public-private partnerships aimed at significantly reducing the burden of HIV incidence among young girls …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
